arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lipocine Inc.

LPCN
$2.14 ▲ +0.01 (+0.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lipocine Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.7M
Dividend Yield
Revenue Growth -82.3%
Op. Margin None
ROIC -71.6%
FCF / Share $-1.79
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.98M
↓ -82.3%
Net Income Profit after all expenses
$-9.63M
↓ -115371.9%
Operating Margin Operating profit as % of sales
-10.3%
↓ -152.9%
FCF / Share Free cash flow per share
$-1.79
↓ -629.3%
Long-Term Debt Long-term obligations
$1.67M
↓ -26.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
13
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 61 quarters